Johnson & Johnson (JNJ) 117.38 $JNJ
Watch for Johnson & Johnson to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Fri Jun 24, 1:16PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $115.00 to a high of $117.12. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $116.18 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 117.38 (+0.92)
New Stock Research Reports for June 24, 2016
Sheraz Mian - Zacks Investment Research - Fri Jun 24, 1:09PM CDT
New Stock Research Reports for June 24, 2016
KO: 45.08 (+0.22), JNJ: 117.38 (+0.92), GE: 31.19 (+0.41), V: 78.23 (+1.70), WFC: 47.91 (+0.94), CRM: 82.28 (+1.66)
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 117.38 (+0.92), ANIP: 56.27 (+3.48), NVS: 80.67 (+0.96)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Support at $116.45
Comtex SmarTrend(R) - Fri Jun 24, 9:20AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $117.15 today and have reached the first support level of $116.91. Analysts will be watching for a cross of the next downside pivot targets of $116.45 and $115.75.
JNJ: 117.38 (+0.92)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 117.38 (+0.92), MU: 14.05 (+1.33), PXD: 160.59 (+1.84), GILD: 83.37 (+0.92), EOG: 84.50 (+0.90), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), GOOGL: 714.87 (+4.40), CVX: 104.44 (+2.15), MSFT: 51.91 (+0.92)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 47.90 (+0.57), JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), LGND: 115.11 (+1.28), BMY: 72.64 (+0.33), AMPH: 16.15 (+0.56)
Johnson & Johnson (JNJ) Breaks Through Resistance at $116.97
Comtex SmarTrend(R) - Tue Jun 21, 8:33AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $116.70 and have already reached the first level of resistance at $116.97. Should the shares continue to rise, the resistance pivots of $117.41 and $118.11 will be of interest.
JNJ: 117.38 (+0.92)
Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce highlighted as Zacks Bull and Bear of the Day
JNJ: 117.38 (+0.92), HLI: 24.59 (+0.75), CM: 81.40 (+1.22), CVGI: 5.55 (+0.35)
Top Stock PIcks for the Week of June 20th
Panel Of Zacks Experts - Zacks Investment Research - Mon Jun 20, 1:02PM CDT
A large cap pharmaceutical company, and a foreign bank with strong metrics top this week's picks.
JNJ: 117.38 (+0.92), CM: 81.40 (+1.22)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), KURA: 2.69 (+0.04), BMY: 72.64 (+0.33)
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:23PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has entered into a definitive merger agreement with QLT Inc. (QLTI).
ABT: 39.63 (+0.89), JNJ: 117.38 (+0.92), QLTI: 1.43 (+0.02), AEGR: 1.67 (+0.11)
EIKONIC Wins Consumer Health Category in Global Competition
PR Newswire - Thu Jun 16, 6:27PM CDT
Melbourne-based Eikonic R&D Pty Ltd, "Eikonic" yesterday announced that it is the winner of $100K in a global competition initiated by a partnership between the Queensland Government and Johnson & Johnson Innovation. The competition was seeking novel and disruptive human healthcare innovations to address unmet medical needs. The funding will assist EIKONIC in the development and commercialisation of its nanotechnology-inspired, preventive topical application for the treatment of gum disease.
JNJ: 117.38 (+0.92)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 39.63 (+0.89), JNJ: 117.38 (+0.92), SHPG: 180.29 (+4.91), PFE: 34.59 (+0.12)
US Personal Care Products for the Maternity Market Growth of 2.37% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Este Lauder, Johnson & Johnson, Unilever - Research and Markets
BusinessWire - Tue Jun 14, 2:57PM CDT
Research and Markets has announced the addition of the "Personal Care Products for the Maternity Market in the US 2016-2020" report to their offering.
JNJ: 117.38 (+0.92)
Johnson & Johnson (JNJ) Approaches New Downside Target of $116.22
Comtex SmarTrend(R) - Tue Jun 14, 8:39AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $117.07 and have already reached the first level of support at $116.51. Should the shares continue to fall, the support pivots of $116.22 and $115.37 will be of interest.
JNJ: 117.38 (+0.92)
Watch for Johnson & Johnson to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Fri Jun 24, 1:16PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $115.00 to a high of $117.12. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $116.18 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 117.38 (+0.92)
New Stock Research Reports for June 24, 2016
Sheraz Mian - Zacks Investment Research - Fri Jun 24, 1:09PM CDT
New Stock Research Reports for June 24, 2016
KO: 45.08 (+0.22), JNJ: 117.38 (+0.92), GE: 31.19 (+0.41), V: 78.23 (+1.70), WFC: 47.91 (+0.94), CRM: 82.28 (+1.66)
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 117.38 (+0.92), ANIP: 56.27 (+3.48), NVS: 80.67 (+0.96)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Support at $116.45
Comtex SmarTrend(R) - Fri Jun 24, 9:20AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $117.15 today and have reached the first support level of $116.91. Analysts will be watching for a cross of the next downside pivot targets of $116.45 and $115.75.
JNJ: 117.38 (+0.92)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), AZN: 29.29 (+0.59), GSK: 42.56 (+0.80)
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 117.38 (+0.92), MU: 14.05 (+1.33), PXD: 160.59 (+1.84), GILD: 83.37 (+0.92), EOG: 84.50 (+0.90), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), GOOGL: 714.87 (+4.40), CVX: 104.44 (+2.15), MSFT: 51.91 (+0.92)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 47.90 (+0.57), JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), LGND: 115.11 (+1.28), BMY: 72.64 (+0.33), AMPH: 16.15 (+0.56)
Johnson & Johnson (JNJ) Breaks Through Resistance at $116.97
Comtex SmarTrend(R) - Tue Jun 21, 8:33AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $116.70 and have already reached the first level of resistance at $116.97. Should the shares continue to rise, the resistance pivots of $117.41 and $118.11 will be of interest.
JNJ: 117.38 (+0.92)
Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce highlighted as Zacks Bull and Bear of the Day
JNJ: 117.38 (+0.92), HLI: 24.59 (+0.75), CM: 81.40 (+1.22), CVGI: 5.55 (+0.35)
Top Stock PIcks for the Week of June 20th
Panel Of Zacks Experts - Zacks Investment Research - Mon Jun 20, 1:02PM CDT
A large cap pharmaceutical company, and a foreign bank with strong metrics top this week's picks.
JNJ: 117.38 (+0.92), CM: 81.40 (+1.22)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), KURA: 2.69 (+0.04), BMY: 72.64 (+0.33)
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:23PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has entered into a definitive merger agreement with QLT Inc. (QLTI).
ABT: 39.63 (+0.89), JNJ: 117.38 (+0.92), QLTI: 1.43 (+0.02), AEGR: 1.67 (+0.11)
EIKONIC Wins Consumer Health Category in Global Competition
PR Newswire - Thu Jun 16, 6:27PM CDT
Melbourne-based Eikonic R&D Pty Ltd, "Eikonic" yesterday announced that it is the winner of $100K in a global competition initiated by a partnership between the Queensland Government and Johnson & Johnson Innovation. The competition was seeking novel and disruptive human healthcare innovations to address unmet medical needs. The funding will assist EIKONIC in the development and commercialisation of its nanotechnology-inspired, preventive topical application for the treatment of gum disease.
JNJ: 117.38 (+0.92)
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 4:19PM CDT
Shire plc (SHPG) announced that it will license global rights to all indications of Pfizer's candidate, PF-00547659.
ABT: 39.63 (+0.89), JNJ: 117.38 (+0.92), SHPG: 180.29 (+4.91), PFE: 34.59 (+0.12)
US Personal Care Products for the Maternity Market Growth of 2.37% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Este Lauder, Johnson & Johnson, Unilever - Research and Markets
BusinessWire - Tue Jun 14, 2:57PM CDT
Research and Markets has announced the addition of the "Personal Care Products for the Maternity Market in the US 2016-2020" report to their offering.
JNJ: 117.38 (+0.92)
Johnson & Johnson (JNJ) Approaches New Downside Target of $116.22
Comtex SmarTrend(R) - Tue Jun 14, 8:39AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $117.07 and have already reached the first level of support at $116.51. Should the shares continue to fall, the support pivots of $116.22 and $115.37 will be of interest.
JNJ: 117.38 (+0.92)
